Your browser doesn't support javascript.
SARS-CoV-2 N501Y Introductions and Transmissions in Switzerland from Beginning of October 2020 to February 2021-Implementation of Swiss-Wide Diagnostic Screening and Whole Genome Sequencing.
Goncalves Cabecinhas, Ana Rita; Roloff, Tim; Stange, Madlen; Bertelli, Claire; Huber, Michael; Ramette, Alban; Chen, Chaoran; Nadeau, Sarah; Gerth, Yannick; Yerly, Sabine; Opota, Onya; Pillonel, Trestan; Schuster, Tobias; Metzger, Cesar M J A; Sieber, Jonas; Bel, Michael; Wohlwend, Nadia; Baumann, Christian; Koch, Michel C; Bittel, Pascal; Leuzinger, Karoline; Brunner, Myrta; Suter-Riniker, Franziska; Berlinger, Livia; Søgaard, Kirstine K; Beckmann, Christiane; Noppen, Christoph; Redondo, Maurice; Steffen, Ingrid; Seth-Smith, Helena M B; Mari, Alfredo; Lienhard, Reto; Risch, Martin; Nolte, Oliver; Eckerle, Isabella; Martinetti Lucchini, Gladys; Hodcroft, Emma B; Neher, Richard A; Stadler, Tanja; Hirsch, Hans H; Leib, Stephen L; Risch, Lorenz; Kaiser, Laurent; Trkola, Alexandra; Greub, Gilbert; Egli, Adrian.
  • Goncalves Cabecinhas AR; Laboratory of Virology, University Hospital Geneva, 1205 Geneva, Switzerland.
  • Roloff T; Center for Emerging Viral Diseases, University Hospital Geneva, 1205 Geneva, Switzerland.
  • Stange M; Applied Microbiology Research, Department of Biomedicine, University of Basel, 4056 Basel, Switzerland.
  • Bertelli C; Clinical Bacteriology and Mycology, University Hospital Basel & University of Basel, 4031 Basel, Switzerland.
  • Huber M; Swiss Institute for Bioinformatics (SIB), 1015 Lausanne, Switzerland.
  • Ramette A; Applied Microbiology Research, Department of Biomedicine, University of Basel, 4056 Basel, Switzerland.
  • Chen C; Clinical Bacteriology and Mycology, University Hospital Basel & University of Basel, 4031 Basel, Switzerland.
  • Nadeau S; Swiss Institute for Bioinformatics (SIB), 1015 Lausanne, Switzerland.
  • Gerth Y; Institute of Microbiology, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.
  • Yerly S; Institute of Medical Virology, University of Zurich, 8057 Zurich, Switzerland.
  • Opota O; Institute for Infectious Diseases, University of Bern, 3012 Bern, Switzerland.
  • Pillonel T; Department of Biosystems Science and Engineering, ETH Zurich, 4058 Basel, Switzerland.
  • Schuster T; Department of Biosystems Science and Engineering, ETH Zurich, 4058 Basel, Switzerland.
  • Metzger CMJA; Center for Laboratory Medicine, 9001 Saint Gall, Switzerland.
  • Sieber J; Laboratory of Virology, University Hospital Geneva, 1205 Geneva, Switzerland.
  • Bel M; Center for Emerging Viral Diseases, University Hospital Geneva, 1205 Geneva, Switzerland.
  • Wohlwend N; Institute of Microbiology, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.
  • Baumann C; Institute of Microbiology, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.
  • Koch MC; Federal Office of Public Health FOPH, 3097 Berne, Switzerland.
  • Bittel P; Spiez Laboratory, Federal Office for Civil Protection FOCP, 3700 Spiez, Switzerland.
  • Leuzinger K; Spiez Laboratory, Federal Office for Civil Protection FOCP, 3700 Spiez, Switzerland.
  • Brunner M; Federal Office of Public Health FOPH, 3097 Berne, Switzerland.
  • Suter-Riniker F; Clinical Microbiology, Labormedizinisches Zentrum Dr. Risch, 9470 Buchs SG, Switzerland.
  • Berlinger L; Institute for Infectious Diseases, University of Bern, 3012 Bern, Switzerland.
  • Søgaard KK; Institute for Infectious Diseases, University of Bern, 3012 Bern, Switzerland.
  • Beckmann C; Institute for Infectious Diseases, University of Bern, 3012 Bern, Switzerland.
  • Noppen C; Clinical Virology, University Hospital Basel, 4031 Basel, Switzerland.
  • Redondo M; Transplantation & Clinical Virology, Department of Biomedicine, University of Basel, 4031 Basel, Switzerland.
  • Steffen I; Applied Microbiology Research, Department of Biomedicine, University of Basel, 4056 Basel, Switzerland.
  • Seth-Smith HMB; Institute for Infectious Diseases, University of Bern, 3012 Bern, Switzerland.
  • Mari A; Bioanalytica AG, 6006 Lucerne, Switzerland.
  • Lienhard R; Applied Microbiology Research, Department of Biomedicine, University of Basel, 4056 Basel, Switzerland.
  • Risch M; Clinical Bacteriology and Mycology, University Hospital Basel & University of Basel, 4031 Basel, Switzerland.
  • Nolte O; Viollier AG, 4123 Allschwil, Switzerland.
  • Eckerle I; Viollier AG, 4123 Allschwil, Switzerland.
  • Martinetti Lucchini G; Viollier AG, 4123 Allschwil, Switzerland.
  • Hodcroft EB; Rothen AG, 4002 Basel, Switzerland.
  • Neher RA; Applied Microbiology Research, Department of Biomedicine, University of Basel, 4056 Basel, Switzerland.
  • Stadler T; Clinical Bacteriology and Mycology, University Hospital Basel & University of Basel, 4031 Basel, Switzerland.
  • Hirsch HH; Swiss Institute for Bioinformatics (SIB), 1015 Lausanne, Switzerland.
  • Leib SL; Applied Microbiology Research, Department of Biomedicine, University of Basel, 4056 Basel, Switzerland.
  • Risch L; Swiss Institute for Bioinformatics (SIB), 1015 Lausanne, Switzerland.
  • Kaiser L; ADMED Microbiology, 2300 La Chaux-de-Fonds, Switzerland.
  • Trkola A; Coordination Commission of Clinical Microbiology, Swiss Society of Microbiology, 1033 Cheseaux, Switzerland.
  • Greub G; Clinical Microbiology, Labormedizinisches Zentrum Dr. Risch, 9470 Buchs SG, Switzerland.
  • Egli A; Coordination Commission of Clinical Microbiology, Swiss Society of Microbiology, 1033 Cheseaux, Switzerland.
Microorganisms ; 9(4)2021 Mar 25.
Article in English | MEDLINE | ID: covidwho-1154452
ABSTRACT
The rapid spread of the SARS-CoV-2 lineages B.1.1.7 (N501Y.V1) throughout the UK, B.1.351 (N501Y.V2) in South Africa, and P.1 (B.1.1.28.1; N501Y.V3) in Brazil has led to the definition of variants of concern (VoCs) and recommendations for lineage specific surveillance. In Switzerland, during the last weeks of December 2020, we established a nationwide screening protocol across multiple laboratories, focusing first on epidemiological and microbiological definitions. In January 2021, we validated and implemented an N501Y-specific PCR to rapidly screen for VoCs, which are then confirmed using amplicon sequencing or whole genome sequencing (WGS). A total of 13,387 VoCs have been identified since the detection of the first Swiss case in October 2020, with 4194 being B.1.1.7, 172 B.1.351, and 7 P.1. The remaining 9014 cases of VoCs have been described without further lineage specification. Overall, all diagnostic centers reported a rapid increase of the percentage of detected VOCs, with a range of 6 to 46% between 25 to 31 of January 2021 increasing towards 41 to 82% between 22 to 28 of February. A total of 739 N501Y positive genomes were analysed and show a broad range of introduction events to Switzerland. In this paper, we describe the nationwide coordination and implementation process across laboratories, public health institutions, and researchers, the first results of our N501Y-specific variant screening, and the phylogenetic analysis of all available WGS data in Switzerland, that together identified the early introduction events and subsequent community spreading of the VoCs.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Diagnostic study / Prognostic study Topics: Variants Language: English Year: 2021 Document Type: Article Affiliation country: Microorganisms9040677

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Diagnostic study / Prognostic study Topics: Variants Language: English Year: 2021 Document Type: Article Affiliation country: Microorganisms9040677